Strategic Partners

Over the past five years, we have built a global network and value-creating strategic partnerships. We have established several global partnerships with leading pharmaceutical companies via in-licensing and clinical collaborations.

We will continue to expand our portfolio and explore partnership through strategic collaborations to maximize the value of our pipeline.

Business Development

We will keep seeking strategic collaborations worldwide that maximize the value of our pipeline. We believe such efforts will facilitate the development of a robust, well-diversified and globally competitive pipeline.

Partnerships

- Laekna has entered into a clinical collaboration agreement with Eli Lilly and Company to support and accelerate global clinical development of LAE102 for the treatment of obesity. Lilly is responsible for the execution and funding of a phase I study in the U.S. Laekna retains global rights for LAE102.

- We have obtained exclusive global rights to develop, manufacture and commercialize LAE001, LAE002, LAE003 and LAE005 under our license agreement with Novartis and we are committed to seek additional partnerships to further optimize our product pipeline.

Combination Therapy Strategy

These opportunities include co-developments of novel treatment modalities for our existing clinical stage pipeline to treat drug resistant tumor types by delivering alternative solutions for patients.

Licensing

Laekna is committed to bringing novel therapies to patients with cancer, metabolic diseases and liver fibrosis around the world. We’ve been pursuing strategic partnerships to accelerate the development and commercialization of drug candidates of our pipeline for such important indications with a great unmet medical need.

Guy Rosenthal, Ph.D. MBA

Vice President,Head of Corporate and Business Development

Dr. Guy Rosenthal joined Laekna Therapeutics in 2021 as Vice President, Head of Corporate and Business Development. As part of leading the corporate and business development group, his responsibilities span from searching for and evaluating potential assets, licensing, and alliance management to forming strategic partnerships and defining the company’s commercial strategy. Dr. Rosenthal is based in Los Angeles, California, USA.

Prior to joining Laekna, Dr. Rosenthal served as Business Development Officer at The University of California Los Angeles Technology Development Group (TDG). In his role, he led corporate development and investment efforts, amongst others, to commercialize biopharmaceutical assets, predominantly in the fields of Immuno-Oncology, Immunology, and Computational Biology.

Dr. Rosenthal has also worked with Global R&D of Teva Pharmaceutical Industries (NASDAQ: TEVA) where he led global early-stage partnerships and has led innovative medical research in the Oncology and Neuro-Oncology fields when developing novel drug delivery platforms at VBL Therapeutics (NASDAQ: VBLT). Guy has completed numerous transactions including in/out-licensing of assets and creation of venture startups.

Dr. Rosenthal is also the Founder and Managing Director of The French Horn Fund, a nonprofit impact fund that invests in social enterprises and special-needs populations.

Dr. Rosenthal holds an MBA from UCLA Anderson School of Management, B.Sc in Biotechnology and a Ph.D in both Biochemistry and Molecular Biology, Faculty of Life Sciences at Bar Ilan University, Israel.

Please contact our BD team: bd@laekna.com